Prof Debu Tripathy speaks to ecancer at BGICC 2019 in Cairo about the management of patients progressing on CDK inhibitors.

He explains that due to the rapid introduction of these drugs it is not known what the natural history is of patients progressing on these drugs.

Prof Tripathy discusses whether or not the therapies used previous to CDK inhibitors will hold and what the is biology of patients who progress on CDK inhibitors.